Patents by Inventor Jane Homan
Jane Homan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150284452Abstract: The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.Type: ApplicationFiled: November 13, 2013Publication date: October 8, 2015Applicant: IOGENETICS, LLCInventors: Robert Duane Bremel, Jane Homan, Michael Imboden, Brendan Keough
-
Patent number: 8703134Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: February 6, 2013Date of Patent: April 22, 2014Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of ArizonaInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Publication number: 20130330335Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.Type: ApplicationFiled: March 21, 2011Publication date: December 12, 2013Applicant: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan
-
Publication number: 20130230516Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: February 6, 2013Publication date: September 5, 2013Applicants: Arizona Board of Regents on behalf of the University of Arizona, ioGenetics, LLCInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Patent number: 8394379Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: January 13, 2010Date of Patent: March 12, 2013Assignee: ioGenetics, LLCInventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
-
Publication number: 20100183611Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: January 13, 2010Publication date: July 22, 2010Applicants: IOGENETICS, LLC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan
-
Publication number: 20100111976Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: September 24, 2009Publication date: May 6, 2010Applicant: IOGENETICS, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Patent number: 7566447Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Iogenetics, LLC, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah A. Schaefer
-
Publication number: 20090098121Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: April 16, 2009Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080274095Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: ApplicationFiled: October 19, 2005Publication date: November 6, 2008Inventors: Jane Homan, Michael Imboden, Michael W. Riggs, Stephane Carryn
-
Publication number: 20080269122Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080267943Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Patent number: 7335243Abstract: The present invention relates to apparatus and systems for isolating hazardous agents and organisms from their handlers and the public. In particular, the present invention relates to modular negative pressure biological containment chambers.Type: GrantFiled: April 22, 2003Date of Patent: February 26, 2008Inventors: Jane Homan, Lee H. Thompson
-
Patent number: 7300790Abstract: The present invention relates to non-vaccinal and non-pharmacologic compositions and methods for controlling complex retroviral infections. In particular, the present invention provides transgenic animals expressing a transdominant negative Rex gene product that inhibits retroviral replication.Type: GrantFiled: January 23, 2004Date of Patent: November 27, 2007Assignee: ioGenetics, LLCInventors: Kurt Eakle, Thomas Hope, Eun-A Choi, Jane Homan, Robert D. Bremel
-
Publication number: 20060147442Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: ApplicationFiled: October 20, 2005Publication date: July 6, 2006Applicants: ioGenetics, University of ArizonaInventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah Schaefer
-
Publication number: 20060107635Abstract: The present invention relates to apparatus and systems for isolating hazardous agents and organisms from their handlers and the public. In particular, the present invention relates to modular negative pressure biological containment chambers.Type: ApplicationFiled: April 22, 2003Publication date: May 25, 2006Inventors: Jane Homan, Lee Thompson
-
Publication number: 20050014932Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: May 13, 2004Publication date: January 20, 2005Applicant: IoGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert Bremel
-
Publication number: 20040253581Abstract: The present invention relates to non-vaccinal and non-pharmacologic compositions and methods for controlling complex retroviral infections. In particular, the present invention provides transgenic animals expressing a transdominant negative Rex gene product that inhibits retroviral replication.Type: ApplicationFiled: January 23, 2004Publication date: December 16, 2004Applicant: Gala Design, Inc.Inventors: Kurt Eakle, Thomas Hope, Eun-A Choi, Jane Homan, Robert D. Bremel
-
Publication number: 20040088744Abstract: The present invention provides methods for the production of a transgenic bovine. In particular, the present invention provides methods for generating transgenic bovines with transgenes that enhance the ability of the bovines to metabolize lipids. The present invention thus provides bovines resistant to fatty liver disease. The compositions and methods of the present invention provide a solution to costly disease.Type: ApplicationFiled: September 22, 2003Publication date: May 6, 2004Inventors: Alan Attie, Gregory Bleck, Robert Bremel, Jane Homan